For older adults living with dementia, a medication prescribed to bring sleep may also influence the very outcomes clinicians are trying to prevent: falls, confusion and loss of independence. A new study published in Translational Psychiatry examines how dual orexin receptor antagonists compare with benzodiazepines and Z-drugs in this medically vulnerable population. Led by TH Liu, CC Chu and CY Liu, the research focuses on two of the most serious complications associated with sleep disturbance and sedating medicines—falls and delirium. Its central question is increasingly urgent as clinicians search for insomnia treatments that can improve nighttime rest without adding to the neurological and physical risks already carried by dementia.
Sleep problems are widespread in dementia. People may struggle to fall asleep, wake repeatedly during the night, become unusually active after dark or experience a reversal of the normal sleep-wake cycle. These disturbances can worsen memory, agitation and caregiver exhaustion. Yet sedative treatment is difficult because the aging brain is more sensitive to medicines that suppress alertness and coordination. A drug that produces sleep may also slow reaction times, weaken balance, lower blood pressure or interfere with the brain’s ability to maintain attention. In someone with dementia, even a modest decline in stability can turn a nighttime trip to the bathroom into a serious injury.
The medications compared in the study act through fundamentally different biological pathways. Benzodiazepines enhance the activity of gamma-aminobutyric acid, or GABA, the brain’s principal inhibitory neurotransmitter. By increasing GABA-A receptor signaling, they broadly dampen neuronal activity, producing sedation, muscle relaxation and reduced anxiety. Z-drugs, including agents such as zolpidem, are chemically distinct from benzodiazepines but also act primarily at GABA-A receptor complexes. Their sleep-promoting effects can therefore be accompanied by impaired psychomotor performance, memory disruption and residual morning sedation—effects that may be particularly consequential in frail adults with cognitive impairment.
Dual orexin receptor antagonists, often abbreviated as DORAs, use a more targeted strategy. The orexin system is a network of neuropeptides and receptors that helps stabilize wakefulness, regulate arousal and coordinate sleep with other physiological processes. DORAs block both orexin receptor 1 and orexin receptor 2, preventing wake-promoting signals from keeping the brain alert. Instead of directly and broadly suppressing neuronal activity through GABA, these medicines are designed to reduce the drive for wakefulness and allow sleep to emerge. The distinction has made DORAs an important focus of research into potentially safer treatments for insomnia, although “more targeted” does not automatically mean risk-free.
The new analysis is significant because people with dementia are frequently excluded from large clinical trials or represented in small numbers, leaving uncertainty about how sleep medicines perform in everyday care. Dementia can alter drug absorption, metabolism and sensitivity, while other commonly prescribed medicines may amplify sedation or dizziness. The condition itself can also impair gait, depth perception and judgment. As a result, the risk associated with a sleep medication cannot be separated from the patient’s baseline vulnerability. A comparative study involving real-world older adults with dementia may therefore offer information that conventional trials are not designed to capture.
Falls are not minor events in this population. They can lead to fractures, head injuries, hospitalization and a rapid decline in mobility. A hip fracture, for example, may trigger prolonged immobility, muscle loss, infection or loss of independent living. Sedating medicines may contribute to falls through several pathways: delayed responses, impaired coordination, nighttime confusion and reduced awareness of environmental hazards. Some can also affect postural blood pressure, making a person unsteady when standing. The danger may be greatest shortly after a dose, during the night or in the early morning, when lighting is poor and the brain is transitioning between sleep and wakefulness.
Delirium presents a different but related threat. It is an acute disturbance in attention and awareness that can develop over hours or days, often fluctuating throughout the day. A person with dementia is already at elevated risk because the brain has less cognitive reserve to withstand infection, hospitalization, dehydration, pain or medication effects. Sedatives can blur the boundary between sleep and wakefulness and may make it more difficult to recognize a rapidly changing mental state. Delirium is not simply a temporary worsening of dementia; it is a medical syndrome associated with longer hospital stays, functional decline and increased mortality. Evaluating delirium alongside falls gives the study a broader safety perspective than measuring sleep alone.
The comparison between DORAs, benzodiazepines and Z-drugs also reflects a major shift in how insomnia is being understood. Traditional sedatives often work by turning down brain activity across multiple circuits. Orexin antagonists instead target a system that actively maintains wakefulness. This pharmacological selectivity could, in theory, reduce some forms of cognitive and motor impairment, but the actual balance depends on dose, timing, half-life, coexisting illnesses and the characteristics of individual patients. Older adults may clear medicines more slowly, allowing effects to persist into the morning. Kidney or liver disease, sleep apnea, alcohol use and combinations with opioids or other central nervous system depressants can further change the risk profile.
The study’s title indicates that it investigates the association of these medication classes with falls and delirium, rather than presenting a simple claim that one treatment is universally safe. That distinction matters. Observational comparisons can reveal important patterns, but they may also be influenced by why a drug was prescribed in the first place. Patients receiving benzodiazepines or Z-drugs may differ from those receiving DORAs in age, illness severity, insomnia intensity, prior falls, behavioral symptoms or access to medical care. Researchers use statistical methods to adjust for such differences, yet adjustment cannot eliminate every source of bias. The findings should therefore inform clinical judgment, not replace individualized assessment.
For families and clinicians, the broader message is that treating insomnia in dementia requires more than selecting a pill. Non-drug approaches remain central, including regular daytime activity, exposure to natural light, consistent sleep and wake times, reduction of evening stimulants, management of pain and careful attention to environmental safety. Clinicians may also review whether another medicine is causing nighttime alertness or daytime sedation. When medication is considered, the decision typically involves the lowest effective dose, the shortest reasonable duration and regular reassessment of benefit and harm. A quieter night is valuable, but it must be weighed against mobility, alertness and the ability to remain safely independent.
By placing DORAs alongside two long-established sedative categories, the research addresses one of the most consequential questions in geriatric medicine: can sleep be improved without increasing the cascade of injuries and acute confusion that so often destabilizes dementia care? The answer will depend on the study’s detailed methods, patient population and measured outcomes, but the subject itself is already reshaping the conversation around insomnia treatment. As the number of older adults living with dementia grows, medication safety will be judged not only by whether a person sleeps, but by whether they wake able to walk, think and function without preventable harm.
Subject of Research: Risk of falls and delirium associated with sleep medications in older adults with dementia.
Article Title: Risk of falls and delirium associated with dual orexin receptor antagonists versus benzodiazepines and Z-drugs in older adults with dementia.
Article References: Liu, TH., Chu, CC., Liu, CY. et al. “Risk of falls and delirium associated with dual orexin receptor antagonists versus benzodiazepines and Z-drugs in older adults with dementia.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04394-8
Image Credits: AI Generated
DOI: 10.1038/s41398-026-04394-8
Keywords: dementia, older adults, falls, delirium, dual orexin receptor antagonists, benzodiazepines, Z-drugs, insomnia, sleep medications, geriatric medicine
